RecruitingPhase 1Phase 2NCT07291635

Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine

A Randomized, Observer-Blind, Adaptive, Active Comparator-Controlled, Dose-Ranging, Multicenter, Safety, Tolerability, and Immunogenicity Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine in Adults 18 Years of Age and Older

Sponsor

Aramis Biotechnologies Inc.

Enrollment

728 participants

Start Date

Feb 25, 2026

Study Type

INTERVENTIONAL

Conditions

Influenza

Summary

This Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Commercial Influenza vaccine and a biological treatment called Recombinant Influenza vaccine candidate for people with influenza. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALRecombinant Influenza vaccine candidate

Plant-Based Seasonal Recombinant Trivalent TVLP Influenza Vaccine

BIOLOGICALCommercial Influenza vaccine

Influenza vaccine commercially available on the Canadian market

Locations(7)

Canadian Center for Vaccinology (CCfV) - IWK Health

Halifax, Nova Scotia, Canada

Montreal Heart Institute

Montreal, Quebec, Canada

Vaccine Study Centre of McGill University Health Centre

Pierrefonds, Quebec, Canada

CHU de Québec - Université Laval

Québec, Quebec, Canada

Diex Recherche - Sherbrooke

Sherbrooke, Quebec, Canada

Diex Recherche - Trois-Rivières

Trois-Rivières, Quebec, Canada

Diex Recherche - Victoriaville

Victoriaville, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07291635

Related Trials

Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.

NCT076455341 location

Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies

NCT047721701 location

A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza

NCT07159763181 locations

Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

NCT013864241 location

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

NCT071693181 location